MHRA approves Inqlexzo for high-risk bladder cancer
The UK medicines regulator has approved a new treatment option for some adults with bladder cancer. In its announcement, the Medicines and Healthcare products Regulatory Agency, or MHRA, said it authorised Inqlexzo on 24 June 2026 for adults with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who cannot have, or do not want, radical cystectomy. This is one of those health stories where the official wording can make people switch off, even though the real question is straightforward. What happens when a high-risk bladder cancer has not responded to standard treatment and a patient is not going ahead with bladder removal surgery? The MHRA decision matters because it adds another option for people in that position.
To understand why this matters, it helps to break the diagnosis down. High-risk non-muscle-invasive bladder cancer means the cancer has not grown into the muscle layer of the bladder, but it still carries a serious risk of coming back or becoming more dangerous. BCG-unresponsive means the cancer has not responded well enough to BCG, which is a common treatment placed directly into the bladder to help the immune system attack cancer cells. The study behind this approval involved patients with carcinoma in situ, a high-risk form of bladder cancer found in the bladder lining. In plain terms, this is a group of patients who often need careful decisions made quickly.
Inqlexzo is not swallowed as a tablet and it is not given into a vein. According to the MHRA, it is placed directly into the bladder by a healthcare professional using a catheter, which is a thin tube. The system then releases gemcitabine, a chemotherapy medicine, slowly inside the bladder over about three weeks. After that, it is removed by cystoscopy, a procedure that uses a small camera to look inside the bladder. The idea is to keep the treatment where the cancer is. The MHRA said treatment is given every three weeks for the first six months, then every 12 weeks for up to 18 months, unless the disease comes back, gets worse or side effects become too difficult.
The evidence behind the authorisation came from a clinical study in adults with BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ. The MHRA said 82% of patients achieved a complete response. **What this means:** a complete response does not mean every patient is cured forever. It means that, when doctors checked, there was no detectable sign of the cancer in the bladder at that point. The same MHRA summary said 51% of the people who responded maintained that response for at least 12 months. That makes the results encouraging, while still leaving room for honest caution.
The most commonly reported side effects were mainly linked to the bladder and urinary system. The MHRA listed urinary frequency, urinary tract infection, painful urination, urinary urgency, urinary tract pain, blood in the urine and bladder irritation. That is also a good reminder that medicine approval is not the end of the safety process. Julian Beach, the MHRA's interim executive director of healthcare quality and access, said the regulator would continue to monitor the safety and effectiveness of the system closely. New treatments are watched carefully after approval as more patients begin using them in everyday care.
If someone thinks they may be having a side effect, the first step is to speak to a doctor, nurse or pharmacist. The MHRA also asks people to report suspected side effects through its Yellow Card scheme. Those reports help regulators spot patterns that may not have been obvious during clinical trials. **What MHRA approval means:** it means the regulator has judged that, for the specific group of patients covered by the licence, the expected benefits outweigh the known risks. It does not mean the treatment is right for everyone with bladder cancer, and it does not replace a conversation with a specialist team about personal risk, likely benefit and other treatment choices.
There are a few regulatory details worth keeping in view. The marketing authorisation was granted to Janssen-Cilag Ltd on 24 June 2026, and the MHRA said the product was submitted and approved through the International Recognition Procedure, Route B. The regulator also said the Summary of Product Characteristics and the Patient Information Leaflet would be published on the MHRA products website within seven days of approval. For patients and families, the biggest takeaway is simple. This approval adds a new option in a difficult area of care, especially for adults trying to avoid bladder removal surgery after BCG has stopped working. If you are reading this because of your own diagnosis, the most useful next question is not whether the treatment sounds hopeful in general, but whether it fits your exact case.